Published in Addiction on January 01, 2015
Rapid HIV Testing and Counseling in Drug Abuse Treatment | NCT00809445
Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. J Viral Hepat (2015) 1.40
Cost-Effectiveness of HBV and HCV Screening Strategies - A Systematic Review of Existing Modelling Techniques. PLoS One (2015) 0.80
A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problems. BMC Health Serv Res (2016) 0.75
Acceptability of Rapid Point-of-Care Hepatitis C Tests Among People Who Inject Drugs and Utilize Syringe-Exchange Programs. Open Forum Infect Dis (2016) 0.75
Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients. AIDS Behav (2016) 0.75
Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States. BMC Public Health (2016) 0.75
Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target? Front Pharmacol (2017) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Can the national addiction treatment infrastructure support the public's demand for quality care? J Subst Abuse Treat (2003) 5.97
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care (2008) 5.14
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat (2006) 5.10
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med (2005) 4.79
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction (2001) 3.87
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2013) 3.65
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. AIDS (2010) 3.44
Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology (2001) 2.90
The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med (2010) 2.71
Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol (2001) 2.69
Hepatitis C in the United States. N Engl J Med (2013) 2.63
Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology (2012) 2.59
Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol (2003) 2.42
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology (2006) 2.35
The impact of diagnosis of hepatitis C virus on quality of life. Hepatology (1999) 2.32
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA (2013) 2.00
Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med (2005) 1.97
Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making (2002) 1.94
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology (2007) 1.90
A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol (2009) 1.86
Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis (2008) 1.86
HIV testing and counseling in the nation's outpatient substance abuse treatment system, 1995-2005. J Subst Abuse Treat (2010) 1.84
Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health (2012) 1.82
Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making (2012) 1.81
Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis (2011) 1.81
Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making (1994) 1.66
Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med (2001) 1.65
Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug Alcohol Depend (2007) 1.64
Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health (2002) 1.61
Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med (1996) 1.56
Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat (2000) 1.45
The cost-effectiveness of expanded testing for primary HIV infection. Ann Fam Med (2005) 1.42
Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol (2011) 1.41
Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep (2009) 1.39
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Risk factors and medical follow-up of drug users tested for hepatitis C--can the risk of transmission be reduced? Drug Alcohol Rev (1997) 1.35
Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis (2005) 1.35
Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment. Drug Alcohol Depend (2010) 1.27
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut (2005) 1.24
Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr (2004) 1.21
Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction (2008) 1.20
Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract (2002) 1.17
Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis (2012) 1.14
Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis (2013) 1.14
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One (2013) 1.14
The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat (2010) 1.11
Outcomes of a Hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol (2008) 1.10
Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 1.09
The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology (2013) 1.08
Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis (2009) 1.07
A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health (2013) 1.07
Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess (2002) 1.06
Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health (2011) 1.06
Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scand J Gastroenterol (2009) 1.05
Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010. Am J Public Health (2012) 1.04
Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One (2012) 1.03
Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Med Decis Making (2008) 1.02
Updating the HIV-testing guidelines--a modest change with major consequences. N Engl J Med (2013) 1.01
HIV testing in the nation's opioid treatment programs, 2005-2011: the role of state regulations. Health Serv Res (2013) 1.01
The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend (2012) 1.01
Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS (2008) 1.00
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis (2013) 0.99
HCV and HIV counseling and testing integration in California: an innovative approach to increase HIV counseling and testing rates. Public Health Rep (2007) 0.97
Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States. J Subst Abuse Treat (2011) 0.96
Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat (2007) 0.94
Missed opportunities for hepatitis C testing in opioid treatment programs. Am J Public Health (2013) 0.93
HIV rapid testing in substance abuse treatment: implementation following a clinical trial. Eval Program Plann (2011) 0.92
Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis (2011) 0.88
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS (2014) 0.87
Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. Sex Transm Infect (2009) 0.86
Medical care and alcohol use after testing hepatitis C antibody positive at STD clinic and HIV test site screening programs. Public Health Rep (2007) 0.85
Successful Integration of Hepatitis C Virus Point-of-Care Tests into the Denver Metro Health Clinic. AIDS Res Treat (2013) 0.83
Effectiveness of a screening program for hepatitis C. Dig Dis Sci (2006) 0.78
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS (2005) 5.43
Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr (2009) 5.40
The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis (2010) 3.96
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res (2004) 3.24
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med (2011) 3.08
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr (2015) 2.80
Familias Unidas: the efficacy of an intervention to promote parental investment in Hispanic immigrant families. Prev Sci (2003) 2.57
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis (2006) 2.45
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med (2011) 2.36
HIV/AIDS, undernutrition, and food insecurity. Clin Infect Dis (2009) 2.33
Alcohol consumption and HIV disease progression: are they related? Alcohol Clin Exp Res (2003) 2.32
Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med (2002) 2.30
Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J (2008) 2.30
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28
HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr (2009) 2.24
HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther (2009) 2.18
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med (2009) 2.13
Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med (2010) 2.10
Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One (2010) 2.05
A Comparison of Agent-Based Models and the Parametric G-Formula for Causal Inference. Am J Epidemiol (2017) 2.05
Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA (2013) 2.00
Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making (2002) 1.94
Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis (2012) 1.90
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses (2004) 1.88
Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health (2012) 1.82
Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr (2007) 1.82
A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. Antivir Ther (2005) 1.82
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis (2012) 1.80
Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis (2004) 1.78
Refusing HIV testing in an urgent care setting: results from the "Think HIV" program. AIDS Patient Care STDS (2006) 1.76
Dental examinations as an untapped opportunity to provide HIV testing for high-risk individuals. Am J Public Health (2010) 1.76
Cost-effectiveness of genotype testing for primary resistance in Brazil. J Acquir Immune Defic Syndr (2015) 1.73
Review of complications in a series of patients with known gastro-esophageal varices undergoing transesophageal echocardiography. J Am Soc Echocardiogr (2009) 1.71
Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis (2007) 1.70
Increasing minority research participation through community organization outreach. West J Nurs Res (2006) 1.69
Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis (2003) 1.69
The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther (2007) 1.68
The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr (2011) 1.67
Loss to follow-up in a community clinic in South Africa--roles of gender, pregnancy and CD4 count. S Afr Med J (2011) 1.65
AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis (2012) 1.64
WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. PLoS One (2011) 1.63
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr (2007) 1.61
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS (2008) 1.59
Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr (2010) 1.57
Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. AIDS (2012) 1.57
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis (2007) 1.57
Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med (2005) 1.56
Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis (2010) 1.55
Frequent HIV testing among participants of a routine HIV testing program. Virulence (2010) 1.53
What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. PLoS Med (2012) 1.53
Perceptions of human immunodeficiency virus (HIV) testing services among HIV-positive persons not in medical care. Sex Transm Dis (2005) 1.50
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Efficacy of a clinical decision-support system in an HIV practice: a randomized trial. Ann Intern Med (2012) 1.48
Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acquir Immune Defic Syndr (2007) 1.48
Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One (2010) 1.46
Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis. Ann Intern Med (2016) 1.44
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis (2007) 1.43
A low-effort, clinic-wide intervention improves attendance for HIV primary care. Clin Infect Dis (2012) 1.42
Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am J Public Health (2005) 1.41
Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol (2007) 1.41
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS (2012) 1.40
Predicting virologic failure in an HIV clinic. Clin Infect Dis (2010) 1.39
Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis (2010) 1.38
An HIV prevalence-based model for estimating urban risk populations of injection drug users and men who have sex with men. J Urban Health (2004) 1.38
Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr (2011) 1.34
Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study. BMC Infect Dis (2014) 1.32
Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One (2012) 1.31
Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center. Clin Infect Dis (2003) 1.31
HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS (2007) 1.30
Risk factors for late-stage HIV disease presentation at initial HIV diagnosis in Durban, South Africa. PLoS One (2013) 1.28
Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med Decis Making (2005) 1.28
Structural ecosystems therapy for HIV-seropositive African American women: effects on psychological distress, family hassles, and family support. J Consult Clin Psychol (2004) 1.26
Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS (2012) 1.26
Interventions for seropositive injectors-research and evaluation: an integrated behavioral intervention with HIV-positive injection drug users to address medical care, adherence, and risk reduction. J Acquir Immune Defic Syndr (2004) 1.25
Brief strategic family therapy versus treatment as usual: results of a multisite randomized trial for substance using adolescents. J Consult Clin Psychol (2011) 1.23